NEW YORK (GenomeWeb) – Biocept said this morning that it received notification yesterday from the Nasdaq that it has regained compliance with the exchange's minimum bid listing requirement.

Nasdaq notified the company last November that it had failed to maintain the required $1 per share minimum bid price, and faced delisting if it did not regain compliance within a 180-day grace period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.